HomeCompareTGHI vs PFE

TGHI vs PFE: Dividend Comparison 2026

TGHI yields 2000000.00% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TGHI wins by $1.6247481716182984e+23M in total portfolio value
10 years
TGHI
TGHI
● Live price
2000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.6247481716182984e+23M
Annual income
$147,608,011,402,949,780,000,000,000,000.00
Full TGHI calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — TGHI vs PFE

📍 TGHI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTGHIPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TGHI + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TGHI pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TGHI
Annual income on $10K today (after 15% tax)
$170,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$125,466,809,692,507,310,000,000,000,000.00/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, TGHI beats the other by $125,466,809,692,507,310,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TGHI + PFE for your $10,000?

TGHI: 50%PFE: 50%
100% PFE50/50100% TGHI
Portfolio after 10yr
$8.123740858091492e+22M
Annual income
$73,804,005,701,474,890,000,000,000,000.00/yr
Blended yield
90.85%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

TGHI
No analyst data
Altman Z
-216.9
Piotroski
1/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TGHI buys
0
PFE buys
0
No recent congressional trades found for TGHI or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTGHIPFE
Forward yield2000000.00%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%13.2%
Portfolio after 10y$1.6247481716182984e+23M$49.6K
Annual income after 10y$147,608,011,402,949,780,000,000,000,000.00$26,258.71
Total dividends collected$1.6146053563276882e+23M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: TGHI vs PFE ($10,000, DRIP)

YearTGHI PortfolioTGHI Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$100,010,700$100,000,000.00$9,153$693.39+$100.00MTGHI
2$467,446,731,075$467,339,719,626.17$8,593$849.25+$467446.72MTGHI
3$1,021,215,363,816,662$1,020,715,195,814,411.90$8,336$1,066.78+$1021215363.81MTGHI
4$1,043,112,617,104,109,200$1,042,019,916,664,825,300.00$8,437$1,384.80+$1043112617104.10MTGHI
5$498,482,143,759,731,400,000$497,366,013,259,430,040,000.00$9,013$1,875.40+$498482143759731.38MTGHI
6$111,599,275,650,097,780,000,000$111,065,899,756,274,860,000,000.00$10,306$2,680.72+$111599275650097776.00MTGHI
7$11,738,678,336,351,557,000,000,000$11,619,267,111,405,953,000,000,000.00$12,820$4,101.38+$11738678336351557632.00MTGHI
8$583,674,362,697,175,100,000,000,000$571,113,976,877,278,900,000,000,000.00$17,673$6,826.70+$583674362697175072768.00MTGHI
9$13,894,210,989,607,547,000,000,000,000$13,269,679,421,521,570,000,000,000,000.00$27,543$12,591.86+$1.3894210989607547e+22MTGHI
10$162,474,817,161,829,840,000,000,000,000$147,608,011,402,949,780,000,000,000,000.00$49,560$26,258.71+$1.6247481716182984e+23MTGHI

TGHI vs PFE: Complete Analysis 2026

TGHIStock

Touchpoint Group Holdings, Inc., through its subsidiaries, operates as a software development company in the United States, Hong Kong, China, and the United Kingdom. The company engages in the software development, design, integration, support, and maintenance services of a robust fan engagement platform that enhances fan experience and drives commercial aspects of the sport and entertainment business. Its fan engagement platform also brings users closer to the action by enabling them to engage with clubs, favorite players, peers, and relevant brands through various features, including live streaming, access to limited edition merchandise, gamification, user rewards, third party branded offers, credit cards, and related benefits. The company was formerly known as One Horizon Group, Inc. and changed its name to Touchpoint Group Holdings, Inc. in September 2019. Touchpoint Group Holdings, Inc. was incorporated in 1972 and is based in Miami, Florida.

Full TGHI Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this TGHI vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TGHI vs SCHDTGHI vs JEPITGHI vs OTGHI vs KOTGHI vs MAINTGHI vs JNJTGHI vs MRKTGHI vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.